Clinical Trial Update: LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating LM-108 antibody in combination with sintilimab for locally advanced or metastatic non-small cell lung cancer is currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• LM-108
• Sintilimab (sintilimab)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: NSCLC, PD-1 | Phase 2 | Status: RECRUITING